Results 51 to 60 of about 22,911 (183)

Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited.
Helen L. Zhang   +2 more
doaj   +1 more source

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

open access: yesDrugs, 2018
The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials. Intravenous meropenem/vaborbactam (Vabomere™) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis ...
openaire   +2 more sources

Correlation between Mechanism of Carbapenem Resistance and in vitro Efficacy of Ceftazidime-Avibactam and Meropenem-Vaborbactam on Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa

open access: yesPakistan Armed Forces Medical Journal, 2022
Objective: To determine the mechanism of Carbapenem resistance, type of Carbapenemase produced and in vitro efficacy of Ceftazidime-Avibactam (CAZ-AVI) and Meropenem-Vaborbactam (MEV) against Carbapenem-resistant Enterobacterales and in vitro efficacy ...
Fatima Ali   +5 more
doaj   +1 more source

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

open access: yesDrugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi   +4 more
wiley   +1 more source

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy

open access: yesPharmaceutics, 2023
Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio   +9 more
doaj   +1 more source

Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes

open access: yesJournal of Chromatographic Science, 2020
Abstract A HPLC method was developed and validated to analyze meropenem and vaborbactam simultaneously in murine plasma and saline matrixes. A 60-μL volume of extracted sample was injected onto a 5-μm BDS Phenyl-Hypersil C18 reversed-phase column and analyzed with a UV detector set at 298 nm for the first 4.9 min and switched to 240 nm ...
Christina A, Sutherland   +1 more
openaire   +2 more sources

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections [PDF]

open access: yesClinical Infectious Diseases, 2019
AbstractTwenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days.
Ryan K, Shields   +10 more
openaire   +2 more sources

The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis

open access: yesChemMedChem, Volume 21, Issue 21, 12 November 2026.
Can a single element help address the multifactorial nature of ALS? Boron‐containing compounds combine responsiveness to reactive oxygen species (ROS), neuroprotective activity, and favorable pharmacological properties, offering a distinctive framework for disease modification in a complex disease like ALS.
Nitesh Sanghai   +5 more
wiley   +1 more source

Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies

open access: yesAntimicrobial Agents and Chemotherapy
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are key therapeutic options for infections caused by KPC-producing Klebsiella pneumoniae (KPC-Kp).
Marta Hernández-García   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy